Suppliers / Oxalis Labs

Oxalis Labs

India 2 duplicate records merged Updated 9 July 2026

Oxalis Labs is a finished-dose manufacturer based in India. It appears in 6 regulatory filings across 2 regulators, without an active US DMF or CEP on file. Its filings concentrate with NAFDAC (NG) and CDSCO (India). Its GMP standing is certified by FDA (GH), NCELS (KZ) and US FDA, among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 2 June 2023 as VAI.

0
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
6
filings across 2 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 2 June 2023 VAI US FDA
  • 2 August 2019 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Solan, India 3010868532

Filings and GMP by regulator

Regulator Filings GMP certificates
NAFDAC (NG) 3 1
CDSCO (India) 3 None
FDA (GH) None 1
NCELS (KZ) None 1
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Oxalis Labs comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 2 June 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates